Bionano Genomics stockholders approve issuance of up to 35M shares upon warrant exercise

Bionano Genomics, Inc.

Vote passed: 22.9M for, 6.2M against, 1.4M abstentions, no broker non-votes.
Approval covers Series A and B warrants from July 4, 2024 private placement to institutional investors.
Issuance required for Nasdaq Listing Rule 5635(d) compliance; warrants were already outstanding.
Potential dilutive impact: up to 35M shares vs. ~86M outstanding as of August 12, 2024 record date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.